
Adverse Events in Airway Procedures in Kids: Key Risks
Adverse events occurred in 2% of children who underwent procedures for airway management under general anesthesia, with higher rates in neonates and infants. Risk factors included younger age, the presence of anatomic difficulties, and undergoing anesthesia outside operating rooms.
METHODOLOGY:
Researchers conducted a prospective observational study at 10 tertiary care hospitals in Japan from June 2022 to January 2024, focusing on the incidence of adverse events during airway management in children under general anesthesia.
A total of 16,695 children (mean age, 6.3 years; 41.4% girls; 1.8% neonates and 11.7% infants) received advanced airway management at least once under general anesthesia, with or without regional anesthesia, including tracheal intubation or the placement of a supraglottic airway device.
Data on patient comorbidities, types of surgeries, training levels of anesthesia providers, and practices for airway management were collected.
The primary outcome was the occurrence of adverse events related to airway management procedures during general anesthesia; the secondary outcome was desaturation, defined as a drop in oxygen saturation of at least 10%.
Occurrences of any adverse events, including at least one hemodynamic and airway-related complication, and respiratory adverse events were recorded, and risk factors for adverse events and desaturation were identified.
TAKEAWAY:
Any adverse events occurred in 2% of cases of airway management, and desaturation was noted in 2.3% of cases. The incidence of any adverse events was 5.8% in neonates and 3.3% in infants, higher than that in preschool and school-going children and adolescents.
Increasing age was linked to reduced odds of any adverse events (adjusted odds ratio [aOR], 0.92; P < .001). Insertion of a supraglottic airway device and the use of muscle relaxants at first attempt were also linked to reduced odds of any adverse events.
Factors associated with increased odds of any adverse events included undergoing anesthesia in CT, MRI, or radiation therapy rooms (aOR, 5.7; P = .006); having airway sensitivity (aOR, 1.46; P = .010); and having one (aOR, 1.74; P = .042) or at least two (aOR, 2.82; P = .017) anatomic difficulties.
The odds of desaturation decreased with increasing age (aOR, 0.78; P < .001) but were higher when anesthesia was provided in catheter labs and CT, MRI, or radiology therapy rooms than when provided in operating rooms. Airway management by nonspecialist anesthesiologists and trainees also was linked to higher odds of desaturation than when the intervention was performed by pediatric anesthetists.
IN PRACTICE:
'Our study, focusing specifically on airway management, showed that approximately 21% of neonates and 7% of infants experienced desaturation, which was higher than that in other age groups,' the researchers reported. 'Neonates' unique physiological and anatomical characteristics can explain this hypoxic progression tendency…The higher desaturation incidence in neonates in our study highlights the necessity for shorter tracheal intubation time and higher first-attempt success rates in neonates,' they added.
SOURCE:
This study was led by Taiki Kojima, MD, MPH, of the Department of Anesthesiology at Aichi Children's Health and Medical Center in Obu, Japan. It was published online on July 07, 2025, in Anesthesiology.
LIMITATIONS:
The reliance on self-reported data from anesthesiologists may have introduced reporting bias and inaccuracies. Selection bias could have occurred due to missing cases, and unmeasured confounders may have affected the results. The exact incidence of adverse events by device type remained unclear due to multiple attempts with different devices.
DISCLOSURES:
The J-PEDIA study was funded by grants from the Ministry of Education in Japan. This study received Grants-in-Aid for Scientific Research from the Ministry of Education in Japan. No additional conflicts of interest were disclosed by the authors.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Weekly spin class ‘better than physio' for people with common hip issue
Weekly group spin classes could be more beneficial than physiotherapy for people with a common hip problem, a study suggests. The approach could also be more cost-effective for the NHS and could help tackle waiting times for physiotherapy, according to researchers. Hip osteoarthritis happens when the cartilage in the hip breaks down, causing pain and stiffness. It it estimated that the condition affects about 3.2 million people in the UK. For the trial, experts from Bournemouth University and University Hospitals Dorset (UHD) compared usual physiotherapy care with an eight-week exercise and education programme known as Chain (cycling against hip pain). The study, published in The Lancet Rheumatology, included 211 people, with roughly half assigned to each group. The Chain group attended weekly education sessions from a physiotherapist, lasting around 30 minutes, followed by a 30-minute session of static cycling led by a gym instructor. The effects of treatment on patients were measured by the Hip Disability and Osteoarthritis Outcome Score (HOOS) activities of daily living (ADL) subscale, which assesses how hip problems affect various daily activities. The study found those who completed the cycling classes had a 'statistically significant improvement in patient-reported function after treatment'. Researchers said the method 'showed superior outcomes compared with usual physiotherapy care, and the feasibility of delivering a low-cost, community-based intervention within the NHS was shown'. However, they stress the 'longer-term benefits and broader generalisability warrant further investigation'. Tom Wainwright, a professor of orthopaedics at Bournemouth University and a physiotherapist at UHD, said: 'For the time it takes to treat one patient using standard physiotherapy, we can treat multiple patients in a group session and provide them with better outcomes. 'This has proved to be more cost-effective than standard treatment and so we hope this will contribute to reducing NHS waiting times for physiotherapy treatment in the future.' Professor Rob Middleton, of Bournemouth University and an orthopaedic surgeon at UHD, said: 'Hip replacements cost the NHS over £6,000 per patient, so avoiding surgery for hip problems reduces the burden on the NHS, saves money, and provides better outcomes for patients. 'Now with this new study we can also see the potential for static cycling to save further money for the NHS by bringing down waiting lists for physiotherapy.' Dr Peter Wilson, chief medical officer at UHD, said: 'We are an ageing population and increasingly we are seeing more patients with osteoarthritis that need either surgery or physiotherapy. 'Finding alternative ways to treat these patients could help reduce waiting times and the financial demand on NHS services.' The Chain intervention was first launched in 2013 and patients who wish to take part are referred to UHD from their GP. To bolster access on a national level, experts from Bournemouth University had developed a virtual course on their education app, allowing people to follow the programme from their home or local gym.
Yahoo
an hour ago
- Yahoo
Treatment Resistant Hypertension Market Set to Transform at a CAGR of 5% with Increasing Diagnosis and Treatment of Resistant Patients along with Approval and Development of Newer Therapies During the Study Period (2020-2034)
The treatment-resistant hypertension (TRH) market is expected to grow in the coming years due to the rising prevalence of uncontrolled hypertension and associated cardiovascular risks. Increasing awareness, improved diagnostic practices, and innovations in combination therapies, as well as device-based interventions, are driving market expansion. LAS VEGAS, July 31, 2025 /PRNewswire/ -- DelveInsight's Treatment Resistant Hypertension Market Insights report includes a comprehensive understanding of current treatment practices, treatment resistant hypertension emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Treatment Resistant Hypertension Market Report Resistant hypertension is managed through a combination of nonpharmacological and pharmacological approaches. Resistant hypertension is initially managed with an ACEi or ARB, a CCB, and a long-acting thiazide diuretic; if uncontrolled, spironolactone is recommended as a fourth-line agent, with β-blockers or α-blockers added if further escalation is needed. The diagnosed prevalence of TRH ranges from 10–14% across the 7MM, suggesting a consistent yet notable burden of the condition. In 2024, there were nearly 13 million diagnosed prevalent cases of TRH across the 7MM, with the United States accounting for the highest number, driven by a major contribution by aging population(40+ age group majorly), heightened awareness of hypertension management as leading pharma companies are focusing on treating resistant patients now, along with ian ncrease diagnosis. In the US in 2024, the highest diagnosed prevalence of treatment-resistant hypertension was observed in adults aged 60 and above, while the lowest was seen in the 18–39 age group, reflecting a clear positive correlation between age and hypertension prevalence. According to DelveInsight's analysis, the market size for treatment resistant hypertension was found to be USD 6.8 billion in the 7MM in 2024, and is projected to grow significantly, driven by the anticipated launch of novel therapies and increased adoption of advanced device-based treatments expected to reshape the treatment landscape. TRYVIO, developed by Idorsia Pharmaceuticals, is the first new class of antihypertensive in nearly 40 years, targeting the endothelin pathway by inhibiting ET-1. Approved by the FDA and EMA in 2024 and by the UK's MHRA in January 2025 for use with other drugs in adults with TRH, it was commercially launched in the US in October 2024. With approval still pending in Japan, the market there remains a significant untapped opportunity for future growth. Followed by TRYVIO's launch in 2024, AstraZeneca's Baxdrostat and Mineralys Therapeutics' Lorundrostat are anticipated to enter the US market by 2026. Out of both the therapies, Lorundrostat's pivotal trial interim data is available; however, Baxdrostat's Phase III data is still awaited. Leading treatment resistant hypertension companies developing emerging therapies, such as AstraZeneca, Mineralys Therapeutics, E-Star BioTech, Ionis Pharmaceuticals, Kardigan, Regeneron Pharmaceuticals, Alnylam Pharmaceuticals, Roche, and others, are developing novel treatment resistant hypertension drugs that can be available in the treatment resistant hypertension market in the coming years. The promising treatment resistant hypertension therapies in the pipeline include Baxdrostat (CIN-107), Lorundrostat (MLS-101), MANP, Tonlamarsen (ION904), REGN5381, Zilebesiran (ALN-AGT01), and others. Discover more about the treatment resistant hypertension treatment market @ Treatment Resistant Hypertension Medication Treatment-Resistant Hypertension Market Dynamics The treatment resistant hypertension market dynamics are expected to change in the coming years. Advances in pharmaceuticals and procedures, along with innovations in pharmacogenomics, precision medicine, and digital health platforms, are expanding the landscape of treatment options for TRH by enabling personalized care, enhancing patient engagement and remote management, and necessitating multidisciplinary collaboration among cardiologists, nephrologists, endocrinologists, and other specialists for comprehensive care. Furthermore, potential therapies are being investigated for treatment resistant hypertension, and it is safe to predict that the treatment space will significantly impact the treatment resistant hypertension market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the treatment resistant hypertension market in the 7MM. However, several factors may impede the growth of the treatment resistant hypertension market. Managing TRH often necessitates complex medication regimens and lifestyle modifications, leading to challenges in patient adherence and treatment optimization; however, despite therapeutic advancements, a subset of patients remains resistant to current options, underscoring the need for alternative strategies, even as stringent regulatory and reimbursement hurdles delay new therapy development and adoption, further compounded by the significant economic burden TRH places on healthcare systems, highlighting the urgent need for cost-effective solutions. Furthermore, the treatment resistant hypertension market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the treatment resistant hypertension market growth. Treatment Resistant Hypertension Treatment Market Resistant hypertension is managed through a combination of lifestyle modifications, pharmacological therapy, and, when necessary, interventional procedures. Key lifestyle changes include maintaining a healthy weight through regular exercise and a balanced diet, reducing salt intake, limiting alcohol consumption, and quitting smoking. Pharmacological treatment typically involves a combination of a renin–angiotensin system inhibitor, a long-acting calcium channel blocker, and a diuretic at the highest tolerable doses, preferably as a single-pill formulation. Spironolactone is currently the preferred fourth-line agent, while alternatives include alpha-blockers, beta-blockers, centrally acting sympatholytics, and vasodilators. For patients whose blood pressure remains uncontrolled despite these strategies, options such as renal denervation and emerging drug therapies should be considered. Lifestyle interventions are particularly important, with a recent meta-analysis identifying them as the most effective non-pharmacologic approach, achieving a reduction in office systolic blood pressure by approximately 7.26 mmHg. Dietary patterns such as the DASH and Mediterranean diets, characterized by high intake of fruits, vegetables, whole grains, and low-fat dairy, and low levels of saturated fats and sugars, have shown proven benefit. Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, offers a promising alternative by blocking aldosterone activity even in its absence. While spironolactone remains the standard add-on therapy, its anti-androgenic effects may limit its use, especially in men or those with hyperkalemia. TRYVIO (aprocitentan) marks a significant advancement as the first antihypertensive from a new drug class in over three decades, targeting the endothelin pathway. Approved by the FDA in early 2024, TRYVIO is a convenient once-daily oral therapy that simplifies prescribing and adherence. The removal of the REMS requirement by the FDA signals increased confidence in its safety. Though it's now available for patients at high cardiovascular risk, fluid retention, reported in 18% of patients at higher doses, which may affect its adoption compared to existing options. While Idorsia has not yet revealed a global commercialization partner, the positive Phase III outcomes indicate strong market potential for TRYVIO. To know more about FDA-approved drugs for treatment resistant hypertension, visit @ Treatment Resistant Hypertension Treatment Treatment Resistant Hypertension Pipeline Therapies and Key Companies Several TRH drugs with different mechanisms of action that are in development are aldosterone synthase inhibitors (baxdrostat, lorundrostat), Guanylyl Cyclase A (GC-A) receptor activators (MANP), Natriuretic Peptide Receptor 1 (NPR1) agonists (REGN5381), angiotensinogen expression inhibitors (zilebesiran), and targeting angiotensinogen (tonlamarsen). The success of these candidates could diversify the treatment landscape and intensify competition. Baxdrostat is an oral, small-molecule drug that selectively inhibits aldosterone synthase, the enzyme responsible for producing aldosterone in the adrenal glands. Baxdrostat emerges as a strong contender in the resistant hypertension pipeline, with AstraZeneca positioning it as a potential multi-blockbuster asset. As an oral aldosterone synthase inhibitor, it targets patients with uncontrolled or resistant hypertension. The Phase II results have shown significant reductions in SBP, outperforming TRYVIO, with a favorable safety profile. First, mention the drug's current phase. The Phase III results, expected in the second half of 2025, will be key in validating its commercial and clinical potential. Lorundrostat, another Phase III investigational oral therapy. It is gaining attention as a high-potential entrant in the antihypertensive market. Developed by Mineralys Therapeutics, the drug is a highly selective oral aldosterone synthase inhibitor, and early data positions it as a potential best-in-class option for patients with resistant or uncontrolled hypertension. Positive outcomes from both the Phase II Advance-HTN and Phase III Launch-HTN trials validate its clinical promise, with efficacy surpassing that of TRYVIO in terms of blood pressure reduction. What further strengthens Lorundrostat's profile is its superior selectivity and greater reduction in plasma aldosterone concentration compared to baxdrostat. With approximately four times higher selectivity, the drug may offer a more targeted approach to managing cardiorenal metabolic conditions, a segment with significant unmet clinical needs. The anticipated launch of these emerging therapies are poised to transform the treatment resistant hypertension market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the treatment resistant hypertension market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. Discover more about treatment resistant hypertension drugs in development @ Treatment Resistant Hypertension Clinical Trials Recent Developments in the Treatment Resistant Hypertension Market In May 2025, Q1 presentation, Alnylam Pharmaceuticals and Roche announced plans to release the topline results from the KARDIA-3 study and to initiate a Phase III cardiovascular outcomes trial of zilebesiran in the second half of 2025. In the Q1 2025 presentation, Regeneron Pharmaceuticals announced the initiation of a Phase II clinical trial evaluating REGN5381 for the treatment of uncontrolled hypertension. In March 2025, Idorsia Pharmaceuticals announced that the US FDA had fully released TRYVIO from its REMS requirement. Idorsia has also released from the PMR to conduct a worldwide descriptive study that collects prospective and retrospective data in women exposed to TRYVIO during pregnancy and/or lactation, as these data are no longer needed. In February 2025, Idorsia Pharmaceuticals announced that the exclusivity agreement signed in November 2024 with an undisclosed party for the global rights to aprocitentan had concluded without the party signing the deal as foreseen in the nonbinding term sheet. Treatment Resistant Hypertension Overview Resistant hypertension is characterized by blood pressure that remains elevated at or above 130 mmHg systolic and 80 mmHg diastolic, despite the use of three or four different classes of antihypertensive medications, including a thiazide diuretic, all at their highest tolerated doses. It can also refer to cases where blood pressure is controlled, but only with the use of four or more antihypertensive agents. This definition encompasses both resistant and refractory hypertension in patients whose blood pressure remains uncontrolled despite being on an adequate regimen that includes a diuretic. Individuals who require more than three medications to control their blood pressure may also benefit from referral to a hypertension specialist. The assessment of resistant hypertension begins with confirming the accuracy of blood pressure readings, as mistakes such as using an improperly sized cuff or incorrect arm positioning can lead to misleadingly high values. It is also important to rule out the white coat effect by using validated out-of-office monitoring methods, such as ambulatory or home blood pressure monitoring under clinical guidelines. Automated office blood pressure (AOBP) measurement, which involves repeated readings taken every 1–2 minutes with the patient alone in a quiet room using a specialized oscillometric device, is a useful technique to reduce this effect. Treatment Resistant Hypertension Epidemiology Segmentation The treatment resistant hypertension epidemiology section provides insights into the historical and current treatment resistant hypertension patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The treatment resistant hypertension market report offers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Diagnosed Prevalent Cases of Treatment Resistant Hypertension Gender-Specific Diagnosed Prevalent Cases of Treatment Resistant Hypertension Age-Specific Diagnosed Prevalent Cases of Treatment Resistant Hypertension Treatment Resistant Hypertension Market Report Metrics Details Study Period 2020–2034 Coverage 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan]. Treatment Resistant Hypertension Market CAGR 5 % Treatment Resistant Hypertension Market Size in 2024 USD 6.8 Billion Key Treatment Resistant Hypertension Companies AstraZeneca, Mineralys Therapeutics, E-Star BioTech, Ionis Pharmaceuticals, Kardigan, Regeneron Pharmaceuticals, Alnylam Pharmaceuticals, Roche, Idorsia Pharmaceuticals, and others Key Treatment Resistant Hypertension Therapies Baxdrostat (CIN-107), Lorundrostat (MLS-101), MANP, Tonlamarsen (ION904), REGN5381, Zilebesiran (ALN-AGT01), TRYVIO/JERAYGO, and others Scope of the Treatment Resistant Hypertension Market Report Therapeutic Assessment: Treatment Resistant Hypertension current marketed and emerging therapies Treatment Resistant Hypertension Market Dynamics: Key Market Forecast Assumptions of Emerging Treatment Resistant Hypertension Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Treatment Resistant Hypertension Market Access and Reimbursement Download the report to understand the treatment resistant hypertension market trends @ Treatment Resistant Hypertension Market Report Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary 4 Key Events 5 Epidemiology and Market Forecast Methodology 6 TRH Market Overview at a Glance in the 7MM 6.1 Market Share (%) Distribution by Therapies of TRH in 2024 6.2 Market Share (%) Distribution by Therapies of TRH in 2034 7 Disease Background and Overview 7.1 Introduction 7.2 Symptoms 7.3 Risk Factors 7.4 Pathophysiology of TRH 7.5 Diagnosis 7.6 Treatment 7.7 Diagnostic Guidelines and Recommendations TRH 7.7.1 European Society of Cardiology (ESC) Recommendations for Hypertension 7.8 Treatment Guidelines and Recommendations for TRH 7.8.1 European Society of Cardiology (ESC) Recommendations for Resistant Hypertension (2024) 7.8.2 European Society of Hypertension (ESH) Recommendations of Lifestyle Interventions in Management of Hypertension (2023) 7.8.3 American Heart Association (AHA) Recommendations for Resistant Hypertension (2020) 7.8.4 The Japenese Socitey of Hypertension Guidelines for the Management of Hypertension (JSH 2019) 8 Epidemiology and Patient Population 8.1 Key Findings 8.2 Assumptions and Rationale 8.3 Total Diagnosed Prevalent Cases of TRH in the 7MM 8.4 The United States 8.4.1 Total Diagnosed Prevalent Cases of TRH in the United States 8.4.2 Gender-specific Diagnosed Prevalent Cases of TRH in the United States 8.4.3 Age-specific Diagnosed Prevalent Cases of TRH in the United States 8.5 EU4 and the UK 8.6 Japan 9 Patient Journey 10 Marketed Drugs 10.1 Key Cross 10.2 TRYVIO/JERAYGO (aprocitentan): Idorsia Pharmaceutical 10.2.1 Product Description 10.2.2 Regulatory Milestones 10.2.3 Other Developmental Activities 10.2.4 Safety and Efficacy 10.2.5 Analyst View 11 Emerging Drugs 11.1 Key Cross Competition 11.2 Baxdrostat (CIN-107): AstraZeneca 11.2.1 Product Description 11.2.2 Other Development Activity 11.2.3 Clinical Development 11.2.4 Safety and Efficacy 11.2.5 Analyst View 11.3 Lorundrostat (MLS-101): Mineralys Therapeutics 11.4 MANP: E-Star BioTech 11.5 Tonlamarsen (ION904): Ionis Pharmaceuticals and Kardigan 11.6 REGN5381: Regeneron Pharmaceuticals 11.7 Zilebesiran (ALN-AGT01): Alnylam Pharmaceuticals and Roche 12 TRH: Seven Major Market Analysis 12.1 Key Findings 12.2 Market Outlook 12.3 Key Market Forecast Assumptions 12.4 Conjoint Analysis 12.5 Total Market Size of TRH in the 7MM 12.6 Market Size of TRH by Therapies in 7MM 12.7 The United States Market Size 12.8 EU4 and the UK Market Size 12.9 Japan 13 Unmet Needs 14 SWOT Analysis 15 KOL Views 16 Market Access and Reimbursement 16.1 United States 16.2 EU4 and the UK 16.3 Japan 16.4 Market Access and Reimbursement of TRH 17 Bibliography 18 Report Methodology Related Reports Treatment Resistant Hypertension EpidemiologyTreatment Resistant Hypertension Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the TRH epidemiology trends. Hypertension MarketHypertension Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hypertension companies, including Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc., Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical, among others. Hypertension PipelineHypertension Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hypertension companies, including Gossamer Bio, Addpharma Inc., Insmed Incorporated, Alnylam Pharmaceuticals, 35Pharma Inc., Pfizer, Pharmosa Biopharm Inc., Guangzhou Magpie Pharmaceuticals Co., Ltd., Suzhou Sanegene Bio Inc., JW Pharmaceutical, among others. Tyrosine Kinase Inhibitors MarketTyrosine Kinase Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key TKIs companies, including AstraZeneca, Novartis, AbbVie, Eisai, Pfizer, F. Hoffmann-La Roche, Bristol-Myers Squibb, Bayer, Boehringer Ingelheim, Johnson & Johnson, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ + Logo: View original content: SOURCE DelveInsight Business Research, LLP Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Yahoo
Doctors see surge in hand, foot and mouth cases this summer
Doctors are warning that cases of hand, foot and mouth disease are surging in the eastern U.S. this summer. There are usually some 200,000 reported cases of the viral illness each year, according to the American Medical Association, with spikes typical during summer and fall. But this summer, doctors say they're seeing even more than usual — although why remains unclear. 'I've been practicing pediatrics for about a decade. I don't think I've ever seen this many cases over a period of a few weeks,' Dr. Edith Bracho-Sanchez, a pediatrician at Columbia University Irving Medical Center in New York City, told The New York Times this week. In Philadelphia, doctors told CBS News that the virus was spreading at summer camps, and a pool in the suburb of Chester was closed for a day after a reported infection. "Each of our centers across the Philadelphia and surrounding county area are seeing multiple cases," Dr. Bob Czincila, medical director of Vybe urgent care, said. Health officials in Maryland, New Jersey and Virginia, also told The Times that there have been more outbreaks in their states in 2025 compared to recent years. However, there is little concrete data because the Centers for Disease Control and Prevention does not require that doctors report cases. The doctors have not hypothesized on the reason for the uptick in cases. Hand, foot, and mouth disease commonly spreads at daycares, schools, and through water sources. The illness, which is common in children under the age of five, can cause a painful red rash of blister-like lesions, fever, and mouth sores. Doctors say infection is usually not serious and people recover after a week or 10 days. Still, it is very contagious. Children can spread hand, foot and mouth disease from the day before the rash shows up and for several days after the rash appears, according to the Children's Hospital of Philadelphia. People are often infected by contact with viruses in fecal matter, fluid from blisters, objects and surfaces with virus particles, and virus particles in the air after a person sneezes, coughs, or even just talks. 'Sometimes those small water-filled blisters can rupture and become shallow ulcers as well, especially in the mouth, which can be painful,' Dr. Terry Yen, a pediatrician and chief medical officer at Texas Children's Urgent Care, said. To prevent infection, people should frequently wash their hands, disinfect surfaces, and avoid close contact with others. If you are infected, most cases resolve on their own, but kids with a temperature above 103 degree Fahrenheit or who have rash that spreads to other parts of the body should see a doctor, Dr. Emily Boss, director of pediatric otolaryngology at Johns Hopkins Medicine, told The Times. Treatment can help to alleviate uncomfortable symptoms. People can take pain relievers, although parents should never give aspirin to children. Instead, kids can take Tylenol and Advil in the first three days of illness, when getting ahead of symptoms can make a major difference, Dr. Natasha Burgert, a pediatrician and national spokeswoman for the American Academy of Pediatrics, told The Times. The mouth sores should be left to heal on their own. Try to eat soft foods and make sure to drink enough water to stay hydrated. The sores may make children not want to drink water. With hand, foot and mouth disease, 'you get worried about children, especially younger children, who are not eating or drinking well becoming dehydrated. That would be a concern,' Yen warned. That is why it is important to 'get children to drink more and help make them comfortable by treating the fevers and the pain.' Solve the daily Crossword